Basal cell carcinomas (BCCs) are the most frequent malignant tumors in humans, accounting for 75–80 % of non-melanoma skin cancers (NMSC), and typically involve chronically sun-exposed areas in elderly patients.1,2 In the elderly population, age-related immune system impairment (immunosenescence) may play a significant role in promoting the development of more aggressive, giant or difficult-to-treat BCCS, potentially influencing both tumor behavior and therapeutic response
Sonidegib efficacy and safety in ultra‐nonagenarian patients / Brunello, Camilla; Corio, Andrea; Zanette, Marco; Caposiena Caro, Raffaele Dante; Zalaudek, Iris; Meo, Nicola Di. - In: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. - ISSN 1610-0379. - (2026), pp. "-"-"-". [10.1111/ddg.70307]
Sonidegib efficacy and safety in ultra‐nonagenarian patients
Brunello, Camilla;Corio, Andrea;Zalaudek, Iris;Meo, Nicola di
2026-01-01
Abstract
Basal cell carcinomas (BCCs) are the most frequent malignant tumors in humans, accounting for 75–80 % of non-melanoma skin cancers (NMSC), and typically involve chronically sun-exposed areas in elderly patients.1,2 In the elderly population, age-related immune system impairment (immunosenescence) may play a significant role in promoting the development of more aggressive, giant or difficult-to-treat BCCS, potentially influencing both tumor behavior and therapeutic responsePubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
